Compare Natera Inc. Common Stock (NTRA) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs D Wave Quantum Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while D Wave Quantum Inc trades at $11.86 (market cap $5.08B). The key difference: Natera Inc. Common Stock is far larger — about 11.2× D Wave Quantum Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and D Wave Quantum Inc for 33 Days on average.
| NTRA | QBTS | |
|---|---|---|
Market Cap | $57.03B | $5.08B |
Volume | 1,131,157 | 11,653,341 |
Sector | Health | Technology |
52-Week High | $425.64 | $44.78 |
52-Week Low | $179.42 | $12.03 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $56.18B | $4.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
QBTS (D-Wave Quantum Inc.) trades at $13.38, down 2.62% on the day, reflecting a bearish technical trend amid negative earnings and high valuation metrics. The company reported a net loss of $355.06M on $24.59M revenue for 2025, with a net income margin of -2,001.59%. Recent news highlights ongoing fraud investigations by multiple law firms, though the company continues to advance its quantum computing technology, such as the launch of a gate-model simulator beta program.
The stock presents a high-risk, speculative opportunity with a unanimous analyst buy rating and a consensus price target of $34.38, implying significant upside. However, substantial financial losses, negative cash flow from operations, and legal uncertainties pose severe risks. Investors should weigh the long-term potential of quantum computing against immediate financial instability and litigation overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
